+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Orencia"

Arthritis Monoclonal Antibodies Global Market Report 2024 - Product Thumbnail Image

Arthritis Monoclonal Antibodies Global Market Report 2024

  • Report
  • February 2024
  • 250 Pages
  • Global
From
Graft versus host disease - Pipeline Insight, 2024 - Product Thumbnail Image

Graft versus host disease - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 220 Pages
  • Global
From
US Alopecia Areata - Market Insight, Epidemiology And Market Forecast - 2032 - Product Thumbnail Image

US Alopecia Areata - Market Insight, Epidemiology And Market Forecast - 2032

  • Report
  • November 2023
  • 115 Pages
  • United States
From
From
ORENCIA Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

ORENCIA Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • January 2023
  • 30 Pages
  • Global
From
From
From
From
From
From
From
Rheumatoid Arthritis Market and Forecast Analysis to 2025 - Product Thumbnail Image

Rheumatoid Arthritis Market and Forecast Analysis to 2025

  • Drug Pipelines
  • August 2018
  • 610 Pages
  • Global
From
Psoriatic Arthritis Market and Forecast Analysis 2035 - Product Thumbnail Image

Psoriatic Arthritis Market and Forecast Analysis 2035

  • Drug Pipelines
  • July 2018
  • 503 Pages
  • Global
From
  • 13 Results (Page 1 of 1)
Loading Indicator

Orencia is a biologic drug used to treat immune disorders, such as rheumatoid arthritis, juvenile idiopathic arthritis, and psoriatic arthritis. It is a recombinant human monoclonal antibody that works by blocking the activity of a protein called TNF-alpha, which is involved in the inflammation process. Orencia is administered via subcutaneous injection and is available in both a prefilled syringe and a vial. Orencia is a relatively new drug, having been approved by the US Food and Drug Administration in 2005. It is currently marketed by Bristol-Myers Squibb, and is available in the United States, Canada, Europe, and other countries. The Orencia market is highly competitive, with several other biologic drugs available to treat immune disorders. These include Humira, Enbrel, Remicade, and Simponi. In addition, there are several generic versions of Orencia available in some countries. Companies in the Orencia market include Bristol-Myers Squibb, AbbVie, Pfizer, Merck, and Janssen Pharmaceuticals. Show Less Read more